1 Introduction Migraine, a disorder influenced by genetics and characterized by multiple factors involving neurological, glial, and vascular systems, ranks as the second most debilitating condition worldwide, impacting the health of over one billion individuals globally ( Migraine manifests as recurrent bouts of moderate to severe headache lasting between 4 to 72 h, typically one-sided, and accompanied by nausea, sensitivity to light (photophobia), sensitivity to sound (phonophobia), and/or vomiting ( Omega-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are vital micronutrients for neurological health
Higher doses, typically above 23 grams of combined EPA and DHA daily, are more likely to cause gastrointestinal side effects including diarrhoea
Phase II trials evaluate safety in a larger group of participants and set the dosage schedule for further phases
Low-dose IL-2 therapy in autoimmune and rheumatic diseases